Autolus Therapeutics Presents Positive Results from Pivotal Phase 2 FELIX study in adult r/r B-ALL at ASCO 76% of patients treated with obe-cel in the FELIX study achieved a response (CR/CRi), primary endpoint has been met based on previously communicated interim analysisPotential best in class...

Elevar Therapeutics to Participate in ASCO 2023 and BIO 2023; New Jersey-based Company Secures State License as It Builds Toward Commercialization FORT LEE, N.J., June 01, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating...

Sunstone Therapies to present data on the long-term efficacy of psilocybin therapy in cancer patients with major depressive disorder (MDD) at the ASCO 2023 Annual Meeting Sunstone Therapies to present data on the long-term efficacy of psilocybin therapy in cancer patients with major depressive disorder (MDD) at the ASCO 2023 Annual Meeting Rockville, Maryland, May...